Sequel Med Tech has officially launched its twiist automated insulin delivery system nationwide, moving beyond its controlled release to make the device available to clinicians and people with diabetes across the country.

The twiist system, powered by the Tidepool Loop algorithm, automatically adjusts basal insulin delivery using CGM data and predicted glucose levels. It is the first AID system to directly measure insulin volume with every microdose, using Sequel's iiSure Technology to detect delivery issues and alert users up to 9x faster than other systems. The device is cleared for individuals aged six and older with type 1 diabetes.

On the integration front, Eversense 365, the implantable CGM from Senseonics, now works with twiist, giving users a longer-wear sensor option alongside Abbott's FreeStyle Libre 3 Plus. Sequel also has plans to integrate the DBLG2 algorithm from Diabeloop in 2027, further expanding user choice within the platform.

We have been covered twiist closely, including a full review of the pump, an iPhone app demo, a site change walkthrough, and a deep dive into the system for All Access members. Our founder Justin Eastzer will also soon be trying the Eversense 365 with twiist, so stay tuned for his firsthand experience.

If you want to learn more about twiist, check out our review and other content we have published on the system here.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.